Treating Neonatal Opioid Withdrawal

The rise in opioid use in the United States has an unpleasant residual effect; an increase in pregnant women suffering from an opioid use disorder. Subsequently, there is a need to treat an increasing number of infants with neonatal opioid withdrawal syndrome (NOWS). This condition can lead to devastating effects for the infant, including severe withdrawal symptoms and development issues.

How is healthcare meeting this challenge? Luckily, clinicians, researchers, and healthcare companies are working on solutions.

On this episode of Vital Spark, a Spark Biomedical podcast, Dan Wagner, Chief Commercial Officer of Spark Biomedical, spoke with two people from the Medical University of South Carolina. They are actively involved in treating this disorder. Dorothea Jenkins, M.D., Professor of Pediatrics, Medical University of South Carolina Division of Neonatology, and Bashar Badran, Ph.D., Assistant Professor in the College of Medicine Department of Psychiatry and the Behavioral Sciences Medical University of South Carolina, spoke about their combined efforts utilizing translational therapies with neurostimulation on babies with NOWS.

Jenkins and Badran discuss:

The effects of certain opioids on the neurology of the brains of babies

New non-evasive brain stimulation treatments to combat NOWS

Learnings from utilizing auricular neurostimulation on babies with NOWS

“We are on track towards the better understanding of reasonable, high-ranking hypothesis that may be the reason why we get such beneficial effects of auricular neurostimulation,” Badran said.”

Dorothea Jenkins, M.D. is a professor of Pediatrics at the Medical University of South Carolina Division of Neonatology who does research and translational therapies for babies with brain injuries. She collaborates with Dr. Bashar Badran on treating babies with neurostimulation with brain injury who are trying to learn motor skills.

Bashard Badran, Ph.D., is an assistant professor in the College of Medicine Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina. He is a neuroscientist who works on brain stimulation research and device development.

 

Follow us on social media for the latest updates in B2B!

Image

Latest

What the Future Looks Like if We Get It Right
What the Future Looks Like if We Get It Right
December 30, 2025

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Read More
data center infrastructure
AI Is Forcing a Rethink of Data Center Infrastructure at Every Level
December 29, 2025

The data center industry is being redefined by AI’s demand for faster, denser, and more scalable infrastructure. According to McKinsey, average rack power densities have more than doubled in just two years. It went from approximately 8 kW to 17 kW, and is expected to hit 30 kW by 2027. Global data center power demand is projected…

Read More
Emergency department
How Predictive AI Is Helping Hospitals Anticipate Admissions and Optimize Emergency Department Throughput
December 24, 2025

Emergency departments across the U.S. are under unprecedented strain, with overcrowding, staffing shortages, and inpatient bed constraints converging into a throughput crisis. The American Hospital Association reports that hospital capacity and workforce growth have lagged, intensifying delays from arrival to disposition. At the same time, advances in artificial intelligence are moving from experimental to operational—raising…

Read More
Mission
Why Is the Mission of Benchmark So Important
December 23, 2025

As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…

Read More